© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Among the 11 patients evaluated for efficacy, 9 patients (81.8%) had objective responses at 28 days.